MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2024 financial results and provide a business update at 8:30 a.m. ET on Thursday, August 8, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees ...

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a novel modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macul ...

• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the third cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a novel modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macu ...

文章核心观点 - 公司Ocugen(OCGN)在医疗行业中表现出色,年初至今的收益率达到131.3%,远高于医疗行业平均5.7%的收益率 [5] - 同样在医疗行业中表现出色的还有Organon(OGN),其年初至今的收益率为44.5% [6] - Ocugen属于医疗-生物医药和遗传学行业,该行业平均收益率为-4%,而Ocugen的表现远超行业平均水平 [7] - Organon属于医疗服务行业,该行业年初至今收益率为4.6% [8] 行业总结 医疗行业 - 医疗行业包含1042家公司,目前在Zacks行业排名中位列第7位 [2] - 医疗行业年初至今平均收益率为5.7% [5] 医疗-生物医药和遗传学行业 - 该行业包含501家公司,在Zacks行业排名中位列第86位 [7] - 该行业平均收益率为-4%,而Ocugen的表现远超行业平均水平 [7] 医疗服务行业 - 该行业包含58家公司,在Zacks行业排名中位列第91位 [8] - 该行业年初至今收益率为4.6% [8] 公司表现 Ocugen(OCGN) - 公司目前Zacks排名为2(买入) [3] - 过去3个月内,公司全年盈利预测上调9.2%,显示分析师对公司前景看好 [4] - 公司年初至今收益率达到131.3%,远高于医疗行业平均水平 [5] Organon(OGN) - 公司目前Zacks排名为1(强烈买入) [6] - 过去3个月内,公司当前年度每股收益预测上调5.3% [6] - 公司年初至今收益率为44.5% [6]

•  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial•  DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved to ...

•  Established Medium Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial•  DSMB Determination to Proceed with High Dose Cohort Dosing MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved t ...

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "Each clinical milestone achieved by OCU400 brings us closer to providing a one-time treat ...

MALVERN, Pa., June 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-time trea ...

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs ...

NEW YORK, June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and reminds investors of the June 10, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Contac ...